AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...

AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.